Clinical Trials in Illinois

Showing 1201-1220 of 19,692 trials

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

NCT05992935

The purpose of the Part A Phase 1 of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 and mRNA-1405 in healthy adult participants 18 to 49 years of age and 60 to 80 years of age. The purpose of Part B Phase 2 and Part C Phase 2 is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 in healthy adult participants (18 to 80 years of age).

Norovirus Acute Gastroenteritis

ModernaTX, Inc.1,407 participantsStarted Aug 2023

Long Beach, California, United States • Longmont, Colorado, United States • Hollywood, Florida, United States +13 more locations

RECRUITINGPhase 140 miles

Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

NCT05500807

Von Willebrand Disease (VWD) is the most common inherited bleeding disorder affecting up to 0.1% of the population, is usually characterized by mucocutaneous bleeding, HMB, surgical bleeding or other hemostatic challenges. Severe bleeding events require VWF concentrates administered solely through intravenous access. Emicizumab (Hemlibra) is a monoclonal bispecific antibody developed to bind activated FIX and FX and mimic FVIII cofactor functionality. Hemlibra is administered via subcutaneous injection rather than intravenous infusion. The hypothesis of this study is that Emicizumab is safe and efficacious for prophylaxis in severe VWD and concomitant VWD/hemophilia patients.

Von Willebrand Disease, Type 3Concomitant VWD and Hemophilia

Bleeding and Clotting Disorders Institute Peoria, Illinois40 participantsStarted Nov 2022

Orange, California, United States • Redwood City, California, United States • Coral Gables, Florida, United States +9 more locations

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

Find Trials by Condition in Illinois

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

The Lilac Device Trial

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Cryoprobe Versus Forceps for Transbronchial Biopsy

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection

ADAPT - A Patient Registry of the Real-world Use of Orenitram®

Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

Open-Label Study of 18F-mFBG for Imaging Neuroblastoma

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC